TY - JOUR
T1 - Recommendations for living donor kidney transplantation Recomendaciones para el trasplante renal de donante vivo
AU - Frutos, Migeul Ángel
AU - Valentín, María de la Oliva
AU - Alonso-Melgar, Ángel
AU - Alonso, Juana
AU - Fernández, Constantino
AU - García-Erauzkin, Gorka
AU - González, Esther
AU - González-Rinne, Ana M.
AU - Guirado, Luis
AU - Gutiérrez-Dalmau, Alex
AU - Huguet Perez, Jordi
AU - López del Moral, José Luis
AU - Musquera, Mireia
AU - Paredes, David
AU - Redondo, Dolores
AU - Revuelta, Ignacio
AU - Van-der Hofstadt, Carlos J.
AU - Alcaraz, Antonio
AU - Alonso-Hernández, Ángel
AU - Alonso, Manuel
AU - Bernabeu, Purificación
AU - Bernal Blanco, Gabriel
AU - Breda, Alberto
AU - Cabello, Mercedes
AU - Caro-Oleas, José Luis
AU - Cid, Joan
AU - Diekmann, Fritz
AU - Espinosa, Laura
AU - Facundo, Carme
AU - García, Marta
AU - Gil-Vernet, Salvador
AU - Lozano, Miquel
AU - Mahillo, Beatriz
AU - Martínez, María José
AU - Miranda Serrano, Blanca
AU - Oppenheimer, Federico
AU - Palou, Eduard
AU - Pérez-Saez, María José
AU - Peri, Lluis
AU - Rodríguez Faba, Óscar
AU - Santiago, Carlos
AU - Tabernero, Guadalupe
AU - Hernández, Domingo
AU - Domínguez-Gil, Beatriz
PY - 2022
Y1 - 2022
N2 - This Guide for Living Donor Kidney Transplantation (LDKT) has been prepared with the sponsorship of the Spanish Society of Nephrology (SEN), the Spanish Transplant Society (SET), and the Spanish National Transplant Organization (ONT). It updates evidence to offer the best chronic renal failure treatment when a potential living donor is available. The core aim of this Guide is to supply clinicians who evaluate living donors and transplant recipients with the best decision-making tools, to optimise their outcomes. Moreover, the role of living donors in the current KT context should recover the level of importance it had until recently. To this end the new forms of incompatible HLA and/or ABO donation, as well as the paired donation which is possible in several hospitals with experience in LDKT, offer additional ways to treat renal patients with an incompatible donor. Good results in terms of patient and graft survival have expanded the range of circumstances under which living renal donors are accepted. Older donors are now accepted, as are others with factors that affect the decision, such as a borderline clinical history or alterations, which when evaluated may lead to an additional number of transplantations. This Guide does not forget that LDKT may lead to risk for the donor. Pre-donation evaluation has to centre on the problems which may arise over the short or long-term, and these have to be described to the potential donor so that they are able take them into account. Experience over recent years has led to progress in risk analysis, to protect donors' health. This aspect always has to be taken into account by LDKT programmes when evaluating potential donors. Finally, this Guide has been designed to aid decision-making, with recommendations and suggestions when uncertainties arise in pre-donation studies. Its overarching aim is to ensure that informed consent is based on high quality studies and information supplied to donors and recipients, offering the strongest possible guarantees.
AB - This Guide for Living Donor Kidney Transplantation (LDKT) has been prepared with the sponsorship of the Spanish Society of Nephrology (SEN), the Spanish Transplant Society (SET), and the Spanish National Transplant Organization (ONT). It updates evidence to offer the best chronic renal failure treatment when a potential living donor is available. The core aim of this Guide is to supply clinicians who evaluate living donors and transplant recipients with the best decision-making tools, to optimise their outcomes. Moreover, the role of living donors in the current KT context should recover the level of importance it had until recently. To this end the new forms of incompatible HLA and/or ABO donation, as well as the paired donation which is possible in several hospitals with experience in LDKT, offer additional ways to treat renal patients with an incompatible donor. Good results in terms of patient and graft survival have expanded the range of circumstances under which living renal donors are accepted. Older donors are now accepted, as are others with factors that affect the decision, such as a borderline clinical history or alterations, which when evaluated may lead to an additional number of transplantations. This Guide does not forget that LDKT may lead to risk for the donor. Pre-donation evaluation has to centre on the problems which may arise over the short or long-term, and these have to be described to the potential donor so that they are able take them into account. Experience over recent years has led to progress in risk analysis, to protect donors' health. This aspect always has to be taken into account by LDKT programmes when evaluating potential donors. Finally, this Guide has been designed to aid decision-making, with recommendations and suggestions when uncertainties arise in pre-donation studies. Its overarching aim is to ensure that informed consent is based on high quality studies and information supplied to donors and recipients, offering the strongest possible guarantees.
UR - https://www.scopus.com/pages/publications/85135161487
U2 - 10.1016/j.nefroe.2022.07.001
DO - 10.1016/j.nefroe.2022.07.001
M3 - Artículo
C2 - 36503720
SN - 2013-2514
VL - 42
SP - 5
EP - 132
JO - Nefrologia
JF - Nefrologia
ER -